---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-21-005470"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:10:09.258639+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences reports Q3 net loss of ~$1.4M; cash $19.7M after $12.5M private placement

## Summary
- Net loss ~$1.4M for Q3 2021; R&D expenses up 36.1% to $0.8M, G&A up 17.5% to $0.9M.
- Ended Q3 with cash ~$19.7M and working capital ~$19.5M after July $12.5M private placement.
- XCART platform progressing toward IND-enabling studies; issued US patent for co-administration with personalized vaccine.
- PolyXen royalty income ~$0.3M from Takeda sublicense in Q3; partner Pharmsynthez filed Epolong registration in Russia.

## SEC filing metadata
- accession: 0001683168-21-005470
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316821005470/0001683168-21-005470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316821005470/xenetic_i8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-21-005470
- JSON: https://secwatch.observer/filing/0001683168-21-005470.json
- Plain text: https://secwatch.observer/filing/0001683168-21-005470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.